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up evenly at n= 3 each. ConClusions: Pharmaceutical manufacturers are using 
innovative patient access schemes to gain access in emerging markets and are 
doing so by finding ways to drive down overall patient spend. While we were able to 
archetype innovative patient access schemes into three categories, it is important 
to note that many schemes incorporate elements from across the categories identi-
fied. Finally, when designing a scheme, pharmaceutical companies must take into 
account a host of factors including country level dynamics, company assets and 
strategy, and particulars of scheme design.
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objeCtives: To define the possible ways of participation of patients in the deci-
sion-making processes in Slovakia. To analyze the current status of patients in 
the reimbursement process in Slovakia and to define barriers to the participa-
tion. Methods: To identify the relevant literature, a survey was carried out using 
a search engine to the literature in PubMed 2000-2013. The survey was carried out 
using the following key words: “Patient participation”, “Patient choice”, in combina-
tion with the terms “Priority Setting”, “Innovation” or “Pharmaceutical Innovation”. 
Materials with those keywords were found, as well as through a Web browser. We 
performed analysis of the Slovak legislation, which regulates the status of patients 
in the reimbursement process and the comparison of this with other legislative 
standards, governing the status of citizens in public processes. There has also been 
evaluated legislative consultation process, which took place during the years 2010 
and 2011. Results: Actually the patients can (as the whole public) only view all 
documents relevant to reimbursement, since they are not a “registered” partici-
pant of the process. They are 3 possibilities to comment the process according to 
relevant legislation: send a writing comment to the MoH, draw up a petition, file a 
complaint. In the period 2010 – 2011, before the legislation change, the MoH received 
318 comments, from that 140 were from public. ConClusions: The whole process 
is totally transparent and visible via internet site of MoH. The status of patients (e.g. 
patient representatives) in the process declined since the last change of legislation 
from 1.12.2011. Due to the introduction of WTP threshold for ICER/QALY is also the 
introduction of innovative drugs more restrictive as before, what makes the pos-
sibilities of patient participation in reimbursement process even more important.
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objeCtives: We evaluated the data of license registry of Ukraine on 01.01.2014. 
Extemporaneous medicines are presented in 426 pharmacies, about 3% of the total 
number in Ukraine. The range of extemporaneous formulations in Ukraine is sig-
nificant, it is complemented by modern specifications physicians. Methods: We 
analyzed the 1570 prescriptions on extemporaneous dosage forms of various doc-
tors in few Lviv pharmacies during 2013-2014. Results: We found that 53 names 
of substances used active substances and excipients. That should be noted that 
different formulations are made: medicine, tinctures, solutions, suspensions, drops, 
ointments, pastes, suppositories, powders. Among the most commonly prescribed 
by doctors’ prescriptions are liquid dosage forms, topical solution (solution furacillin 
0.02% - 500.0; rivanol 0.05%, 0.1% - 500.0; hydrogen peroxide 3% - 500 0, a solution 
of methylene blue 1% - 10.0), solutions for electrophoresis, nasal drops (solution 
collargolum 3% - 10.0 and protargolum 2% - 10.0), thymi water, soothing medicine 
quater, Pavlova, Ravkin. These pharmacies offer 26 solutions to supply hospitals. 
Also popular are antiflu powder (antigrypin) and vitamins, care products for face 
and body. Among soft medicines dominate ointment for wound healing (Lesyuk 
ointment, kalanhoie ointment) and for the treatment of sinusitis, Unna paste (for 
healing venous wounds), suppositories for hemorrhoid treatment (by prof. Maslyak) 
and antifungals (solution Kastelyani and various ointment). Currently, there are 
difficulties in ensuring substances, including missing: dibazol, diphenhydramine, 
collodion 4% lithium chloride, paracetamol, pepsin, yellow mercury, sulfur purified, 
diluted hydrochloric acid 8.4%, zinc sulfate, extract althey root, aminophylline, 1% 
citral alcohol solution. ConClusions: Extemporaneous medicines are economi-
cally available, the average costs of solutions are 4-12 UAH (1 Euro= 16.0UAH), eye 
drops- 6-18 UAH, ointments - 5 - 15 UAH, which is 40-85% less than the manufactory 
drugs. That’s cost-effective therapy and provide individualized drug treatment for 
children, elderly, and chronically patients in Ukraine.
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objeCtives: In 2014, the Irish Department of Health and Children (DoHC) published 
a policy document outlining the introduction of Universal healthcare by 2019. The 
impetus for adopting Universal healthcare is multi-faceted; the main driver being 
the current two-tier, private/public delivery system limits access to care for sub-
groups of the population. Inequality in access to care and clinical outcomes has been 
extensively published in Ireland; the implementation of Universal health care will 
aid in reducing this inequality as well as stabilise variation in resource use across 
socio-economic groups providing more efficient and equitable delivery of health 
care. The aim of this review was to catalogue what basic care is offered at the popula-
tion level across Universal delivery models in Europe and document disease-specific 
resource use and health outcomes as well as organisation around reimbursement 
structures for purposes of informing policy in Ireland. Methods: EU-27 countries 
were classified by health care delivery systems according to data available from 
HealtH CaRe use & PoliCy stuDies – equity and access
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objeCtives: To describe and to compare the Colombian multidimensional poverty 
index (MPI) ’s trends against Gini coefficient (GC) and inequities in maternal mor-
tality and neonatal mortality since 1997 to 2011. Methods: An ecological study 
was performed. MPI and Gini coefficient were obtained from National Statistics 
Department´s (DANE) databases. The Maternal Mortality Rate and Neonatal 
Mortality Rate were estimated and standardized by age and sex respectively. The 
Attributable Fraction (AF) was estimated as the inequity indicator for these two vari-
ables estimating the excess of risk by geographical exposure. We estimate the trend 
and behavior among MPI’s Colombian version and health inequities and disparities 
indicators over time from 1997 until 2011. Results: A substantial change was evi-
dent in the MPI 51% decrease (1997-2011) and 40%, (2003-2011) decreasing from 0.6 
to 0.3 (2003-2011), whilst Maternal Mortality attributable Fraction (MMAF) showed 
a 3% increase, rising from 83.4% to 86.2% (2000-2008), and a slight reduction for 
Neonatal Mortality attributable fraction (NMAF) 1.6%, (2000-2008) decreasing from 
88.9% to 88.4%. At the same time. GC evidenced a 1% decrease between 2000-2011 
decreasing from 0.57 to 0.54. ConClusions: The established MPI for Colombia in 
the last decade had a descending trend and did not resemble the stationary behavior 
of the major inequity indicators calculated for the country in the same time span. 
Consequently, there was an undervalued perception over the issues where affected 
population were not target of requested interventions. It is therefore important to 
question the validity of measures used to quantify the poverty (MPI’s Colombian 
version) in order to reconsider the strategies of interventions where health inequity 
is an important referent to create control and intervention measures.
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Quality and risk management together, are prerequisites of patient safety which 
forms the basis of health care quality management activity. objeCtives: To explore 
the prevailing organizational climate-in terms of clinical governance’ factors 
“Climate of blame and Punishment” and “A planned and integrated QI program and 
proactive risk management”, in Greek hospitals and to compare nurses’ perceptions 
with those of the rest health professionals on the particular factors. Methods: It 
is a cross-sectional study, including a representative sample of all specialties of 
employees working in a public and a private Greek hospital. The validated Clinical 
Governance Climate Questionnaire (CGCQ) was filled by Nn= 261 nurses and Noth 
prof= 198 other professionals (response rate: 79%). A lower score signifies greater 
satisfaction in a particular concept. Data mining took place from May to August 
2012. Data analysis was performed with the SPSS 19.0 and included factor analysis, 
t-test, X2test and regression analysis The two-tailed significance level was set ≤ 
0.05. Results: The results for the factors “Climate of blame and Punishment” and “A 
planned and integrated QI program and proactive risk management”, demonstrated 
a slightly positive trend (Means: 2.73 and 2.28 respectively) in the total population. 
Nurses, appear to perceive more negatively the climate related to: i) protected time 
for Quality Improvement initiatives (p< 0.05), ii) systematic assessment of clinical 
risks (p< 0.001), iii) sharing of a common vision (p< 0.05), iv) dissemination of Risk 
prevention policies (p< 0.001), v) proactive risk management (p< 0.05), vi) systematic 
evaluation of Human Resources development needs (p< 0.001), vii) equal employee’s 
valuation regardless of professional background (p< 0.05). ConClusions: The views 
of nurses are essential, as they are important and direct factors of care provision. 
The assessment of climate produces conclusions which if exploited properly, can 
mark the beginning and support the effort of continuous improvement of patient 
safety.
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objeCtives: Emerging markets are a major priority for pharmaceutical manufac-
turers, and continue to grow as areas of interest for many firms. However, coverage 
from 3rd party payers, whether public or private, is often limited, and as a result 
the patient is the primary payer. Pharmaceutical companies must devise innovative 
strategies in order to provide access to patients while driving sales. In this study, we 
aimed to assess pharmaceutical company strategies to address patient affordability 
in emerging markets. Methods: We undertook a secondary research horizon scan 
utilizing public resources to examine a variety of strategies, including innovative 
patient access schemes across emerging markets. We then filtered a total of n= 14 
schemes in emerging markets into several categories in order to create archetypes 
and to identify common themes and trends. Examples from a number of countries 
and regions were considered, including Brazil, China, India, sub-Saharan Africa, 
and others. Results: We categorized n= 14 patient access schemes into three main 
categories/archetypes: Licensing and Technology Transfer, Differential Pricing and 
Cost Offset Programs, and Value Added Services based on the primary objectives and 
characteristics of each scheme. A majority of programs fell under the Differential 
Pricing and Cost Offset programs (n= 8), with the other two categories splitting 
